Eli Lilly and Company (NYSE:LLY) Stock Price Down 0.6% - Should You Sell?

Eli Lilly and Company (NYSE:LLY - Get Free Report) shares traded down 0.6% during trading on Tuesday . The stock traded as low as $740.85 and last traded at $751.22. 1,296,108 shares traded hands during trading, a decline of 63% from the average session volume of 3,532,019 shares. The stock had previously closed at $755.57.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Guggenheim reiterated a "buy" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price target for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. UBS Group dropped their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Truist Financial boosted their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research report on Monday, February 3rd. Finally, StockNews.com upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $1,011.37.

Eli Lilly and Company Trading Up 3.3%

The firm has a market capitalization of $717.65 billion, a PE ratio of 64.67, a PEG ratio of 1.40 and a beta of 0.48. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The business has a fifty day moving average price of $797.84 and a two-hundred day moving average price of $806.14.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business's revenue for the quarter was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.58 earnings per share. Analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date of this dividend is Friday, May 16th. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This represents a 14.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.13% of the company's stock.

Institutional Investors Weigh In On Eli Lilly and Company

Several hedge funds and other institutional investors have recently made changes to their positions in LLY. RMR Wealth Builders raised its position in shares of Eli Lilly and Company by 2.3% during the 4th quarter. RMR Wealth Builders now owns 4,686 shares of the company's stock worth $3,618,000 after acquiring an additional 107 shares in the last quarter. Grassi Investment Management raised its position in shares of Eli Lilly and Company by 0.3% during the 4th quarter. Grassi Investment Management now owns 79,512 shares of the company's stock worth $61,383,000 after acquiring an additional 225 shares in the last quarter. Elevate Capital Advisors LLC purchased a new position in Eli Lilly and Company during the 4th quarter worth approximately $262,000. Wolff Wiese Magana LLC grew its stake in Eli Lilly and Company by 3.0% during the 4th quarter. Wolff Wiese Magana LLC now owns 1,797 shares of the company's stock worth $1,387,000 after buying an additional 52 shares during the last quarter. Finally, ARS Wealth Advisors Group LLC grew its stake in Eli Lilly and Company by 1.3% during the 4th quarter. ARS Wealth Advisors Group LLC now owns 2,113 shares of the company's stock worth $1,631,000 after buying an additional 27 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.